It has been reported that IL8 promoted angiogenesis by recruiting CXCR2+ neutrophils, which provided the growing neoplasm with pro-angiogenic mediators (VEGFs and MMPs), implicating IL8 as a druggable immunotherapeutic target [48, 49]. This evidence concerns the gene CXCR2 and neoplasm.